Company Information

Kitov Pharma is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, achieved the primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the U.S. FDA for patients suffering from osteoarthritis pain and hypertension. NT-219, which is developed by Kitov's majority-owned subsidiary, TyrNovo Ltd., is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

Tags:

Price Data
NASDAQKTOV
Recent News
Mar 14, 2019

TEL AVIV, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an agreement to acquire FameWave Ltd., a...

Feb 7, 2019

Highlights & Achievements in 2018 and to Date: - Approximately $13 million cash on hand at the beginning of 2019 based on a reported cash balance of $6.7 million on December 31, 2018, plus net...

Jan 16, 2019

TEL-AVIV, Israel , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE:KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements...

More >


print email